

Development of a recombinant protein-based ELISA for diagnosis of larval cyathostomin infection

MAIRI C. MITCHELL^{1†}, THOMAS TZELOS^{1†}, IAN HANDEL²,
HAMISH E. G. MCWILLIAM^{1,3}, JANE E. HODGKINSON⁴,
ALASDAIR J. NISBET¹, VITALIY O. KHARCHENKO⁵,
STEWART T. G. BURGESS¹ and JACQUELINE B. MATTHEWS^{1*}

¹ Moredun Research Institute, Pentlands Science Park, Edinburgh EH26 0PZ, Scotland, UK

² Royal Dick School of Veterinary Studies, University of Edinburgh, Edinburgh EH25 9RG, Scotland, UK

³ Department of Microbiology and Immunology, Doherty Institute of Infection and Immunity, The University of Melbourne, Parkville, Victoria 3010, Australia

⁴ Department of Infection Biology, Institute of Infection and Global Health, University of Liverpool, Liverpool L69 7ZJ, England, UK

⁵ I.I. Schmalhausen Institute of Zoology NAS of Ukraine, vul B Khmelnytskogo 15, Kyiv 01030, Ukraine

(Received 1 February 2016; revised 23 February 2016; accepted 26 February 2016; first published online 13 May 2016)

SUMMARY

Cyathostomins are ubiquitous nematodes of horses. Once ingested, they can spend a substantial time as encysted larvae in the intestinal wall. The larvae can comprise up to 90% of the total burden, with up to several million worms reported in individuals. These stages can emerge in large numbers to cause life-threatening colitis. Direct methods for detection of encysted larval burdens in live horses do not exist. Previously, two antigen complexes were identified as promising markers for infection. A component of these, cyathostomin gut associated larval antigen-1 (Cy-GALA-1), was identified following immunoscreening of a complementary DNA library. Serum immunoglobulin G(T) (IgG(T)) responses to Cy-GALA-1 were shown to inform on larval infection. Sequence analysis of polymerase chain reaction products amplified from individual worms indicated that Cy-GALA-1 was derived from *Cyathostomum pateratum*. As cyathostomin infections always comprise multiple species, a diagnostic test must account for this. Here, segments of the *Cy-gala* gene were isolated from four common species, *Cyathostomum catinatum*, *Cylicocyclus ashworthi*, *Cylicostephanus goldi* and *Cylicostephanus longibursatus*, and the associated proteins expressed in recombinant form. The specificity and immunogenicity of each protein was confirmed. Each protein was assessed by enzyme linked immuno sorbent assay (ELISA) for its ability for informing on the presence of encysted larval infection and the level of burden.

Key words: nematode, cyathostomin, encysted larvae, ELISA, diagnosis.

INTRODUCTION

Parasitic nematodes of the group Cyathostominae are a potential cause of serious disease in equids. These parasites have a high prevalence and most horses that graze encounter them (Matthews, 2008). Cyathostomins exist as a group of around 50 species (Lichtenfels *et al.* 2008); however, most infections comprise 5–10 common species, with low numbers of rarer species present (Chapman *et al.* 2002a). Species compositions are similar across regions, with the same group appearing as the most prevalent globally (Ogbourne, 1976; Reinemeyer *et al.* 1984; Mfitlodze and Hutchinson, 1990; Bucknell *et al.* 1995; Gawor, 1995; Lichtenfels *et al.* 2001; Collobert-Laugier *et al.* 2002). For all species, the life cycle involves larval encystment in the wall of the large intestine and larvae can persist for up to 2 years (Gibson,

1953; Smith, 1976; Murphy and Love, 1997). In some horses, encysted larvae can constitute up to 90% of the total burden, with some individuals harbouring millions of worms (Dowdall *et al.* 2002). Encysted larvae are important in the pathogenesis of cyathostomin infections, because these stages can emerge in great numbers to cause larval cyathostominosis, a colitis syndrome that can be fatal in up to 50% of cases (Giles *et al.* 1985; Love *et al.* 1992). Larval cyathostominosis is most commonly observed in horses of 2–5 years of age (Reid *et al.* 1995); however, animals can have a lifelong susceptibility to infection and disease has been observed in horses of all ages (Mair, 1993). The potential clinical effects of cyathostomins are confounded by high levels of anthelmintic resistance in these nematodes, with resistance to benzimidazole and pyrantel compounds almost ubiquitous in some regions (Kaplan, 2002; Matthews, 2014). The macrocyclic lactones are the most commonly used anthelmintics in horses and reduced efficacy against cyathostomins has been reported for ivermectin in Brazil (Canevar *et al.* 2013), with several studies reporting shortened strongyle egg

* Corresponding author: Moredun Research Institute, Pentlands Science Park, Edinburgh EH26 0PZ, Scotland, UK. E-mail: jacqui.matthews@moredun.ac.uk
† These authors contributed equally to this work.

reappearances period following ivermectin (Geurden *et al.* 2014; Relf *et al.* 2014) and moxidectin (Rossano *et al.* 2010; Relf *et al.* 2014) treatment. A shortened helminth egg reappearance period is regarded as an early indicator of resistance (Sangster, 1999), highlighting the threat of resistance to all available classes of broad spectrum anthelmintic.

Anthelmintic targeting of encysted larvae is now common practice in control programmes in some regions (Stratford *et al.* 2014). Moxidectin and fenbendazole (administered over 5 consecutive days) are registered for this purpose (Matthews, 2008); however, because of high levels of resistance to fenbendazole (Reinemeyer *et al.* 2016), moxidectin is the only remaining compound effective against encysted larvae, so its efficacy needs to be preserved. To address this, a reduction in treatment frequency is recommended (Matthews, 2014). This can be achieved by improving grazing practices to reduce transmission via the environment, combined with specific targeting of treatments based on strongyle egg shedding (Nielsen *et al.* 2006, 2014; Lester and Matthews, 2014). Such protocols do not address encysted larvae within individuals. Indeed, horses with sizeable encysted larval burdens often have no or low egg shedding (Dowdall *et al.* 2002). Because of these issues, a test that informs on the presence or burden of encysted larvae would facilitate anthelmintic targeting of these stages and would assist in the definitive diagnosis of larval cyathostomiasis, a challenge in practice due to the non-specific nature of the associated clinical signs (Giles *et al.* 1985).

Previously, these authors identified two native antigen complexes that showed promise as diagnostic markers of encysted larval infection (Dowdall *et al.* 2002, 2003, 2004). The antigen preparations are labour intensive to prepare and rely on a continual source of equine tissue. Thus, steps were taken to identify genes that encode protein components of the complexes to develop a recombinant protein-based test. One component, cyathostomin gut associated larval antigen-1 (Cy-GALA-1) protein, was identified by immunoscreening a larval complementary (c)DNA library using sera from infected ponies (McWilliam *et al.* 2010). Sequence analysis of polymerase chain reaction (PCR) products amplified from DNA from individual worms indicated that Cy-GALA-1 was derived from the common species, *Cyathostomum pateratum*, so Cy-GALA-1 was redesignated Cy-GALA-pat (McWilliam *et al.* 2010). Recombinant Cy-GALA-pat was demonstrated to be the target of serum immunoglobulin G(T) (IgG(T)) responses in infected, but not in uninfected horses, and exhibited no reactivity to antibody in serum from horses specifically infected with non-cyathostomin helminths. In experimentally- and naturally-infected horses, antigen-specific IgG(T) levels were significantly higher than those in cyathostomin negative animals, with antigen-specific IgG(T) levels shown to have a

significant positive correlation with encysted larval burden (McWilliam *et al.* 2010). As horses invariably harbour a range of cyathostomin species, a diagnostic test will need to take account of this complexity. Here, recombinant GALA proteins were generated from four common cyathostomin species and the specificity and immunogenicity of each examined. These proteins were assessed by the enzyme linked immuno sorbent assay (ELISA) for their ability to predict the presence of encysted larval infection and the level of burden.

MATERIALS AND METHODS

Parasite material

Individual adult cyathostomins were removed from the large intestinal luminal contents of naturally-infected horses at post mortem (Dowdall *et al.* 2002). The worms were identified to species by morphological means based on the key of Lichtenfels *et al.* (2008). Cyathostomin encysted larvae were recovered by pepsin-hydrochloric (HCl) digestion or by manual removal from the mucosa and sub-mucosa as described previously (Dowdall *et al.* 2002).

Serum samples

For immunoblotting and ELISA experiments, sera from different sources were used to examine the specificity and immunogenicity of each recombinant protein. First, sera were used from six ponies that had been raised in helminth free (HF) conditions in the UK. Three of these ponies (Ponies 102, 103, 106) were maintained HF until necropsy and the remaining three (Ponies 101, 104, 105), were subjected to a 'trickle' infection regime with cyathostomin third stage larvae as described previously (Murphy and Love, 1997). The sera from these ponies were used as a source of cyathostomin negative control sera (classified here as HF) and cyathostomin positive control sera (classified here as cyathostomin infected, CI). A CI serum pool comprised samples from the three experimentally infected ponies taken at 12–16 weeks post-infection. These time points were selected on the basis of high serum IgG(T) reactivity in these ponies to native encysted larval antigen complexes identified in Dowdall *et al.* (2002). A pool of negative control serum was prepared from samples obtained from the three HF ponies. These serum pools were used as controls in all subsequent immunoblotting and ELISA studies. Serum was also available to examine, by immunoblotting, the cross reactivity of the GALA recombinant proteins to those present in other nematode species. In these studies, sera from horses infected with *Strongylus edentatus* or *Strongylus vulgaris* (Klei *et al.* 1982) or with *Parascaris equorum* or *Strongylus westeri* (Dowdall *et al.* 2003) were used. To assess and measure the immunogenicity of the recombinant proteins, serum was used that was derived from naturally or

experimentally infected horses from the UK and USA. For some of these groups, enumerated nematode burden data were available, which allowed comparison of antigen specific IgG(T) levels with level of burden. For immunoblotting studies, serum IgG(T) reactivity was assessed in a serum pool from seven naturally-infected horses from the UK, each of which had a high total mucosal burden (TMB) of >100 000 encysted larvae (Dowdall *et al.* 2002). In the immunoblotting studies, serum IgG(T) reactivity was also assessed in a pool of sera obtained from 11 clinical cases of larval cyathostominosis. These horses were classified as clinical cases based on their presenting signs and the detection of large numbers of cyathostomin larvae in their faeces (Hodgkinson *et al.* 2003). Rabbit sera were also used in the immunoblotting studies. Here, sera raised to the native antigen complex (Dowdall *et al.* 2003) and to Cy-GALA-pat (McWilliam *et al.* 2010) were used. Antigen reactivity in rabbit serum obtained before and after immunisation was compared. In the ELISA studies, serum samples from individuals from various populations were tested for reactivity to each GALA protein. First, sequential serum samples from the six experimental ponies (above) were used in time course experiments to measure levels of antigen specific IgG(T) in each pony from before infection until 16 weeks after the start of the 'trickle' infection. Antigen specific IgG(T) levels were also measured in a group (UK+) of horses that comprised 25 horses sampled at a UK abattoir (Dowdall *et al.* 2004), as well as the three experimentally infected ponies as described above (Murphy and Love, 1997). Cyathostomin burdens in these horses were quantified with the TMB and total worm burden (TWB) calculated as described previously (Dowdall *et al.* 2004). Antigen-specific serum IgG(T) levels were also measured in each of the 11 larval cyathostominosis cases from the UK (UK+Clin). Serum IgG(T) levels in these cohorts were compared with those in serum obtained from the six experimental ponies before infection (UK-, Murphy and Love, 1997). Several groups of CI horses from the USA (US+) were also assessed for serum IgG(T) levels to each antigen. One group comprised 10 naturally-infected horses (Monahan *et al.* 1996). Another comprised 38 ponies subjected to various cyathostomin experimental infection/treatment regimens (Monahan *et al.* 1997, 1998; Chapman *et al.* 2002b). Serum IgG(T) levels in these cohorts were compared with those in US cyathostomin free ponies that were infected with *S. vulgaris*, *P. equorum* and *S. westeri* (US-).

Sub-cloning and recombinant protein expression of Cy-Gala proteins from an additional four cyathostomin species

Like Cy-GALA-pat, two of the additional proteins were derived from clones selected by

immunoscreening (McWilliam *et al.* 2010). Similar to the strategy used to ascribe a species identity to *Cy-gala-pat*, nucleotide sequences in these two clones were compared with *gala* sequences obtained by polymerase chain reaction (PCR) amplification from individual identified worms of various species. Based on this analysis, the clones were ascribed to the common species, *Cylicocycylus ashworthi* (sequence named as *Cy-gala-ash*) and *Cyathostomum catinatum* (sequence named as *Cy-gala-cat*). For recombinant protein expression, *Cy-gala-ash* and *Cy-gala-cat* sequences were used to design primers to facilitate PCR amplification of *Cy-gala* encoding sequence (minus the signal peptide sequence) from phage plaque eluates from respective clones selected by immunoscreening (McWilliam *et al.* 2010). Sequences encoding restriction enzyme sites were incorporated into each primer to facilitate unidirectional cloning [the nucleotide sequences reported in this paper have been submitted to GenBank, accession numbers: JN596964 (*Cy-gala-ash*), JN596966 (*Cy-gala-cat*), JN596967 (*Cy-gala-gol*), JN596968 (*Cy-gala-lon*)]. The primer sequences were: *Cy-gala-ash* (*SacI*, *NotI* sites underlined) sense 5'-ATTCGAGCTCCCATGAAGAACTTCGTTCGTCAC-3', antisense 5'-AGCTTGCGGC CGCATATCTTCTATCCGTGTTGAG-3'; *Cy-gala-cat* (*NcoI*, *NotI* sites underlined) sense 5'-ATGGCCATGGATGAGGATCGTGAAGAACATCGC-3', antisense 5'-AGCTTGCGGCCGCATCTCTTTCATCTGTGTTGAGTCC-3'. The PCR conditions were as follows: 0.5 µM primers, 0.2 mM dNTPs and 1.5 mM MgCl₂, with cycling conditions, 94 °C for 2 min, 30 cycles at 94 °C for 15 s, with an annealing temperature of 54 °C (*Cy-gala-ash*) or 53 °C (*Cy-gala-cat*) for 30 s, and 72 °C for 60 s, with a final cycle of 72 °C for 7 min. Amplifications were performed using Platinum Taq (Invitrogen) in combination with 2 µL of each phage plaque eluate in a reaction volume of 50 µL. For size determination, PCR products were analysed on 1.1% w/v agarose TAE gels using a TrackIt 100 bp DNA Ladder (Invitrogen) and stained with 1× GelRed (Biotium). Next, the expression plasmid (pET-22b(+), Novagen) and each PCR product were digested with the appropriate restriction enzymes and ligation of the PCR amplicons performed using T4 ligase (Promega). The derived plasmids were transformed into *Escherichia coli* JM109 competent cells (Promega) and selected on ampicillin-Luria-Bertani (LB) agar. For each species, one colony containing plasmid with an insert of the correct size was subjected to plasmid purification (Wizard Plus SV Miniprep kit, Promega) and the insert sequenced in full to confirm identity. On confirmation of sequence identity, plasmids were transformed into *E. coli* BL21-CodonPlus(DE3)-RIL competent cells (Stratagene) for expression of recombinant Cy-GALA-ash and Cy-GALA-cat. Recombinant

protein expression was induced as described in McWilliam *et al.* (2010). Similar to Cy-GALA-pat (McWilliam *et al.* 2010), Cy-GALA-cat was soluble and present in the bacterial lysate supernatant. This protein was purified directly on a HisTrapHP column (GE Healthcare), eluted in increasing concentrations of imidazole, then dialysed with 20 mM sodium phosphate, 0.5 M NaCl (pH 7.4), and stored at -20°C . The Cy-GALA-ash protein was insoluble, so purification and dialysis were carried out as above, with the exception that 8 M urea was added to all buffers.

For isolation of *gala* sequences from *Cylicostephanus goldi* and *Cylicostephanus longibursatus*, conserved primers (sense 5'-ATGAACAAA ACGTTAACATTTCTC-3', antisense 5'-AGGAG GTGATGATGGCATG-3') were designed using all of the *gala* sequences described above and used to PCR-amplify a portion of the *gala* gene from single, identified adult *C. goldi* and *C. longibursatus* using cDNA synthesized as described in Lake *et al.* (2009). The PCR products were cloned into pGEM[®]-T Easy vector (Promega), plasmid preparations made and the inserts sequenced in both directions. To generate PCR products for sub-cloning for protein expression, species-specific primers were designed using the *C. longibursatus* and *C. goldi* sequences obtained from individual identified worms. For each, primer sequences (*SacI* and *NotI* restriction sites underlined) were: *Cy-gala-gol* sense 5'-ATTCGAGCTCCCAAGGTGTCATGGCCC TATTTG-3', antisense 5'-ATTAGCGGCCG CCAGGTATCTTCTATCCGTGTTTCAG-3', and for *Cy-gala-lon* sense 5'-ATTCGAGCTCCCAAG GTGTCATGGACCTTTTGG-3', antisense 5'-ATTAGCGGCCGCATATCTTCTATCCGTGT TGATTCCG-3'. PCR conditions were as above, except that 0.25 μM primers and 0.4 μL of Platinum Taq were used in reaction volumes of 100 μL , and 30 amplification cycles performed with an annealing temperature of 58°C . The PCR products and vector were digested with *SacI* (Promega) and *NotI* (Promega) and ligated into pET-22b(+) vector. Plasmids were transformed into *E. coli* JM109 Competent Cells (Promega) and selected on ampicillin-LB agar. Colonies were examined by PCR for the presence of an insert of the correct estimated size using vector-specific primers and plasmid preparations made from two colonies, which were sequenced using the same primers. Clones of the correct sequence were transformed into BL21-CodonPlus(DE3)-RIL cells as above. Recombinant Cy-GALA-lon and Cy-GALA-gol were insoluble, so were prepared and stored in the presence of 8 M urea as above. Nucleotide and amino acid sequence alignments were performed using ClustalW2 (Larkin *et al.* 2007) and sequence identity levels examined using MegAlign 10.0.1 (DNASTAR) based on the ClustalW2 alignments. Signal peptides were identified

using SignalP 4.0 (Petersen *et al.* 2011). Sequences were translated and molecular mass estimated using the Sequence Manipulation Suite (http://www.bioinformatics.org/sms2/protein_mw.html).

Immunogenicity and specificity of recombinant GALA proteins assessed by immunoblotting

To assess immunogenicity and potential cross reactivity of each recombinant protein, binding of IgG(T) in sera from horses infected only with cyathostomins or with single-species experimental infections of non-cyathostomin helminths was investigated (for serum sources, see above). Serum IgG (T) reactivity was also assessed in serum pooled from naturally-infected horses from the UK (UK+) and in a pool of sera from larval cyathostomiasis cases (UK+Clin). Finally, IgG reactivity in rabbit sera raised to a 20 kDa larval antigen complex and to recombinant Cy-GALA-pat (see above) were assessed. For blotting, 0.1 μg of each GALA protein was loaded, per lane, onto a 15-well, 12% NuPAGE gel with SeeBlue Plus2 protein standards used for size estimations (Invitrogen). An additional lane was loaded with 0.1 μg protein. After electrophoresis, this lane was removed and stained with Coomassie blue for comparison with the immunoblots. Blocking, primary, secondary and tertiary antibody steps and blot development were as described in McWilliam *et al.* (2010).

Immunoreactivity of the recombinant GALA proteins assessed by ELISA

Once the immunogenicity and specificity of each new GALA protein was confirmed by immunoblotting, the ELISA was used to evaluate serum IgG(T) levels to each protein in various groups of equids (see above). First, IgG(T) levels to the GALA proteins were assessed in ponies over a time course of experimental infection (Murphy and Love, 1997). Antigen-specific IgG(T) levels were then assessed in cohorts of horses from the UK (UK+) and from the USA (US+) for which the cyathostomin burden was known and in a cohort of larval cyathostomiasis cases (see above). Serum IgG(T) responses to Cy-GALA-pat were compared in these studies. The ELISA plates (96-well flat bottomed Microtiter High binding plates, Greiner Bio-One) were coated with recombinant GALA antigens at $2 \mu\text{g mL}^{-1}$. Each well was coated with 100 μL of antigen in coating buffer (0.1 M carbonate coating buffer, pH 9.6) overnight at 4°C . Plates were washed six times with 0.05% Tween-20 in phosphate buffered saline (PBS) (PBS-T), then blocked using 200 μL block buffer (2% soya powder (Infasoy[™] Cow and Gate Ltd), w/v in PBS), per well for 1 h at 37°C . All serum dilutions were made in block buffer. The plates were washed three times (as

above) and 100 μ L sera (diluted 1:800) added to each well and incubated for 2 h at 37 °C. Each serum sample was tested in triplicate. Plates were washed six times, incubated for 1 h with (100 μ L per well) goat anti-equine IgG(T) whole molecule (Serotec), diluted 1:400 in block buffer. The plates were washed six times, then 100 μ L rabbit anti-goat Ig: HRP conjugate (Sigma), diluted 1:500 in block buffer, added to each well and incubated for 1 h at 37 °C. Reactions were developed by adding 100 μ L *o*-Phenylenediamine dihydrochloride (OPD) solution prepared from SIGMAFAST OPD tablets (Sigma) to each well. After 15 min at room temperature, 50 μ L 2.5 M H₂SO₄ were added to stop the reactions and the absorbance in each well read at 490 nm. On all plates, aliquots from the same pool of CI sera were tested in triplicate as a control for inter-plate variation. The results derived from all samples were then expressed as the percentage optical density (OD) of the CI sample mean for each plate. Minitab 17 Statistical Software for Windows was used to analyse the data. For the different infected groups (UK+, UKClin+, US+), the group medians of the percentage positivity were compared with those of the cyathostomin free horses (UK– and US–) by the Mann–Whitney test. A *P* value <0.05 was taken to indicate statistical significance.

Receiver operator characteristic (ROC) curve analysis

ROC curve analysis was performed to indicate the accuracy of each GALA protein ELISA result relating to cyathostomin infection (positive or negative) and to cyathostomin TMB and TWB by assessing the tradeoff of diagnostic sensitivity *vs* specificity over a range of cut-off values. As an estimate of test accuracy, the area under the curve (AUC) may be interpreted such that; AUC = 0.9–1.0 demonstrates an excellent level of discrimination between positive and negative results; AUC = 0.8–0.9 good discrimination; AUC = 0.7–0.8 fair discrimination; AUC = 0.6–0.7 poor discrimination and AUC = 0.5–0.6 no discrimination (Swets, 1988). All ELISA data were subjected to ROC analysis using Prism 6 (Graphpad Software Inc, USA).

RESULTS

Analysis of GALA sequences from the four additional cyathostomin species

Alignment (Fig. 1) of the derived GALA protein sequences demonstrated that, like Cy-GALA-pat, all sequences from the additional four species contained an N-terminal histidine-rich motif and a highly-conserved domain (Marchler-Bauer *et al.* 2007), the function of which is unknown and which is termed as Domain of Unknown Function 148 in the two most closely related sequences from

Caenorhabditis elegans. Comparative analysis (Table 1) indicated that the sequences were between 83.3% (Cy-GALA-ash) and 92.9% (Cy-GALA-cat) identical to Cy-GALA-pat at the amino acid level. The level of intra-specific identity in the derived amino acid sequences was higher than 90% for all five species examined.

Immunoreactivity and cyathostomin specificity of the recombinant GALA proteins

Coomassie staining of the four new recombinant GALA proteins (Fig. 2A) demonstrated that the approximate size observed for each corresponded to the calculated molecular mass. The immunoblot experiments demonstrated that IgG(T) in sera from HF ponies did not bind to any of the four recombinant GALA proteins, whilst IgG(T) in sera from ponies experimentally infected with cyathostomins (CI sera) bound to all four (Fig. 2B). In terms of cross reactivity to other helminth species, there was no, or negligible, IgG(T) binding to each of the four recombinant GALA proteins observed in sera from horses infected specifically with *P. equorum*, *S. edentatus*, *S. vulgaris* or *S. westeri* (Fig. 2B). To further examine immunogenicity of the proteins in naturally-infected horses, immunoblots were performed using sera pooled from horses that presented at an abattoir and which had high encysted larval burdens. Here, strong reactivity of IgG(T) to all four GALA proteins was observed (Fig. 3A). Likewise, IgG(T) in sera pooled from samples from larval cyathostominosis cases demonstrated strong reactivity to all proteins (Fig. 3B). The GALA proteins also bound IgG in sera from a rabbit immunised with the native 20 kDa complex, originally identified in encysted larvae (Dowdall *et al.* 2003, Fig. 3C). Similarly, IgG in sera from a rabbit immunised with Cy-GALA-pat bound each of the four new recombinant GALA proteins (Fig. 3D). No binding was observed in pre-immunisation sera from either rabbit.

ELISA and ROC curve analysis of serum IgG(T) responses to the recombinant GALA proteins in CI horses

A time course study was performed to analyse serum IgG(T) responses to each new GALA protein in experimentally-infected ponies across a trickle infection (Fig. 4). IgG(T) responses in infected ponies (Ponies 101, 104, 105) were analysed from before infection until 16 weeks after first challenge. GALA-specific IgG(T) in these individuals were compared with those in ponies that remained uninfected (Ponies 102, 103, 106). Similar to previous observations with GALA-pat (McWilliam *et al.* 2010), increases in antigen-specific IgG(T) were observed against all recombinant GALA proteins after

Cy-GALA-pat	MNKILTLFTLVVSAVALAQGVMDLFGEEEGREEHRRHRHSLLPPYLHNVSCEAKWEYFKIV	60
Cy-GALA-cat	-----EDREEHRRHRHSLLPPYLHNVSCEAKWEYFRIV	34
Cy-GALA-gol	MNKILTLFTLVVSAVVLAQGVMALEFGESEEREHRRHRHSLLPPYLHNVSCEAKWEYFKIV	60
Cy-GALA-lon	MNKILTLFTLVVAVVLAQGVMDLFGEEEGREEHRRHRHSLLPPYLHNVSCEAKWEYFKIL	60
Cy-GALA-ash	-----HEELRHHRRHSLLPPYLHNVSCEAKWEYFKIV	32
	* * * * *	:
Cy-GALA-pat	GNRSLTFAEKKKEISEWAKKYNVVDENVASYNAYREKLQEHKKNVSELVSALPNVAVKKVN	120
Cy-GALA-cat	GNRSLTFAEKKKEISEWAKKYNVLDEVASYNAYREKLQEHKKNVSELVSDLPKAVKKVN	94
Cy-GALA-gol	GNRSLTFAEKKKEISEWAKKYNVVDENVASYNAYREKLQEHKKNVSELVSDLPNVAVKKVN	120
Cy-GALA-lon	GNRSLTFAEKKKEISEWAKKYNVVDENVASYNACREKLQEHKKNVSEIIVSNLPNVAVKKVN	120
Cy-GALA-ash	GNRSLTFAEKKKGKSEWAKKYNVVDENVASYNAYREKLQEHKKNVSELVSGLPNAVKKVN	92
	* * * * *: : : * : * * * : * * * * * : * * * * * : * * * * :	
Cy-GALA-pat	DLLDNENQTFRQLYVALRKLGQNPAFYRYVEYINVAVRLRSEEVDQEQRRLSALPFG	180
Cy-GALA-cat	DLLDNENQTFRQLYVALRELGRQNPTLYRYVEYINVAVRRLSEEVDQEQRRLSALPFG	154
Cy-GALA-gol	DLLDNENQTSRQLYVALRELGRQNPAFYRVVEYINVAVRLRKEQDEQERQGTLSALPFG	180
Cy-GALA-lon	DLLDNENQTFRQLYVALRKLGQNPAFYRVVEYINVLVRLRREEFDE-QRRSLSALPFG	179
Cy-GALA-ash	ELLDNENQTPRQLYVALRKLGQNPFVLYRVVEFNVLVRFREDSDQEQRMLSTLPFS	152
	: * * * * *: * * * * *: * * * * *: * * * * *: * * * * *: * * * * :	
Cy-GALA-pat	DHNDNLEE QDFGEQDFFRYVYGFE CARFL LQNGRMFGLNTDRY-	223
Cy-GALA-cat	DNNNDNLEE QDFGEQDFFRYVYGFE CARFL LQNGRMFGLNTDERD-	197
Cy-GALA-gol	ENNNDNLEE QDFGEQDFFRYVYGFE CARFL LQNGRMFGLNTDRRYQ	224
Cy-GALA-lon	DNNDDLEE QDFGEQDFFRYIYGFE CARFIL LQNGRMFGLINTDRY-	222
Cy-GALA-ash	ENN--EEQDLGEQDFQYIYGFE CARFI FQNGRMFGLNTDRY-	192
	: * * * * *: * * * * *: * * * * *: * * * * *: * * * * *: * * * * :	

Table 1. Details of GALA sequences representing recombinant proteins used in the ELISA

GALA protein name	Number of worms sequenced per species (range of intraspecific variation in amino acid sequence as a percentage)	Amino acid identity (%) to Cy-GALA-pat sequence of each clone used for expression	Predicted size of recombinant protein including His tag (kDa)
ash	3 (95.5–97.2)	83.3	25.5
cat	4 (92.9–97.3)	92.9	25.1
gol	4 (90.8–100)	91.3	27.2
lon	2 (97.1–100)	89.8	27.0
pat	5 (94.7–97.6)	100	26.6

These are derived from the species: *Cylicocycylus ashworthi* (ash), *Cyathostomum catinatum* (cat), *Cylicostephanus goldi* (gol), *Cylicostephanus longibursatus* (lon) and *Cyathostomum pateratum* (pat).
Accession numbers of the sequences representative of each clone used for expression for each species are as follows: *Cy-gala-pat* – FJ882059.1, *Cy-gala-cat* – JN596966, *Cy-gala-gol* – JN596967, *Cy-gala-lon* – JN596968, *Cy-gala-ash* – JN596964.

Next, levels of serum IgG(T) to all four new GALA proteins and GALA-pat were compared in equids for which cyathostomin burden data were available, thus allowing comparison of parasitological parameters with specific IgG(T) levels in matched end-point serum samples. Also analysed were GALA-specific serum IgG(T) responses in horses that presented with larval cyathostominosis. First, serum IgG(T) levels were compared in CI groups (UK+, US+, UKClin+) with those in cyathostomin negative groups (UK-, US-) from the UK and the USA. For the UK+ and UKClin+ cohorts, for all five proteins, specific IgG(T) levels were significantly higher than in cyathostomin negative horses




Fig. 2. Specificity of the four recombinant GALA proteins. (A) Coomassie stained sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gel depicting all four new recombinant GALA proteins. ash = *C. ashworthi* recombinant protein; cat = *C. catinatum* recombinant protein, gol = *C. goldi* recombinant protein, lon = *C. longibursatus* recombinant protein, M = molecular weight marker. (B) Immunoblots of each recombinant protein (Cy-GALA-ash, -cat, -gol and -lon) probed for IgG(T) reactivity using sera from helminth free (HF) ponies, experimental cyathostomin infected (CI) ponies and horses infected specifically with *Parascaris equorum* (Pe), *Strongylus edentatus* (Se), *Strongyloides westeri* (Sw) or *Strongylus vulgaris* (Sv). M = molecular weight marker.

(Table 2). Likewise, for the US population, levels of IgG(T) to each protein were significantly higher in the US+ group than in the US- (cyathostomin free) group. ELISA data from horses for which cyathostomin burdens were available were subjected to ROC curve analysis. For all five proteins, GALA-specific IgG(T) levels in equids, which were known to be truly cyathostomin negative (i.e. the UK- and US- groups) were compared with GALA-specific IgG(T) levels measured in CI horses from the UK or the US (Table 3). Here, high AUC values (i.e. >0.9) were obtained for all proteins (AUC values: 'ash' and 'lon' > 'pat' > 'cat' > 'gol'). The highest sum of percentage sensitivity and specificity values generated here were then used to calculate cut-off percentage positivity thresholds for each GALA protein (Table 3). Based on these values, specificity ranged from 82.43% (ash) to 95.95% (cat) and




Fig. 3. Immunogenicity of the recombinant GALA proteins. (A) Immunoblot of each recombinant protein (Cy-GALA-ash, -cat, -gol and -lon) probed for binding of IgG(T) in a pool of serum from UK naturally infected horses, each of which had a total cyathostomin encysted larval burden of >100 000 larvae. (B) Immunoblot of each recombinant protein (Cy-GALA-ash, -cat, -gol and -lon) probed for binding of IgG(T) in a pool of serum from larval clinical cyathostominosis cases from the UK. (C) Immunoblot of each recombinant protein (Cy-GALA-ash, -cat, -gol and -lon) probed for binding of IgG in sera from a rabbit taken before (P) and after (I) immunization with the cyathostomin encysted larval 20 kDa complex (Dowdall *et al.* 2003). (D) Immunoblot of each recombinant protein (Cy-GALA-ash, -cat, -gol and -lon) probed for binding of IgG in sera from a rabbit taken before (P) and after (I) immunization with Cy-GALA-pat (McWilliam *et al.* 2010).

sensitivity from 77.78% (cat, gol) to 100% (ash and pat). When the data were stratified at different cyathostomin TMB thresholds, taking into account that some horses negative for TMB were positive for cyathostomin luminal parasites (Table 4), AUC values and sensitivity and specificity values




Fig. 4. IgG(T) responses in experimentally infected ponies to the four recombinant GALA proteins as measured by the ELISA. Recombinant GALA (A. GALA-ash, B. GALA-cat, C. GALA-gol, D. GALA-lon) protein-specific IgG(T) responses over an experimental trickle infection (Murphy and Love, 1997). Six British native-breed ponies (6–12 months at the time of initial infection) were reared indoors with their dams and considered to be helminth naive prior to the start of the trial. Following weaning at 4 months, the ponies were maintained on a high-fibre pelleted ration and bedded on wood shavings. Three ponies (Ponies 101, 104 and 105) were infected with a total of 3·9 million cyathostomin third stage larvae (L3), administered as a trickle infection of 150 000 L3 by nasogastric tube, three times a week. Ponies 102, 103 and 106 were maintained as uninfected controls. Pony 104 was necropsied at 20 weeks post-infection and the remaining ponies at 60–62 weeks post-infection.

calculated were lower. Next, TWB thresholds were examined to assess if the outputs were likely to be confounded by the half life of GALA-specific serum IgG(T) responses; for example, in equids where there had been recent emergence of previously-encysted larvae or in those that had been administered recently with an effective larvicidal treatment. When the cohort was stratified on the basis of cyathostomin TWB, for all proteins, AUC and sensitivity and specificity values were higher than when the group was stratified on the basis of TMB alone (Table 4). For '0 TWB' threshold, AUC values for IgG(T) responses to all five GALA proteins were high (i.e. >0·9). Finally, the cohort was stratified on the basis of a threshold of 5000 mucosal larvae or TWB. At a cutoff of a TMB of 5000 larvae, AUC values ranged from 0·69 (GALA-ash) to 0·77 (GALA-cat), so giving 'good' discrimination. At a cutoff of 5000 TWB, GALA-cat and GALA-lon (AUC values for both = 0·82) gave the highest values, with AUC values for the other proteins

exceeding 0·7. When the data were partitioned such that the threshold value was 10 000 TMB or TWB, most AUC values generated were <0·7 (data not shown).

DISCUSSION

Cyathostomins have high pathogenic potential in equids due to their capacity to cause life-threatening colitis when encysted larvae emerge from the intestinal wall. For this reason, the administration of anthelmintics that have activity against these developmental stages is regarded by many as an essential component of equine parasite control programmes in developed regions (Nielsen, 2012; Matthews, 2014; Nielsen *et al.* 2014). As it is likely that most horses will not carry life-threatening levels of encysted larvae, the availability of a diagnostic test that can inform on the presence or burden of these stages would help in directing the strategic application of larvicidal anthelmintic treatments.

Table 2. Comparison of serum IgG(T) levels in cyathostomin-infected *vs* non-infected groups from the UK and USA

Groups compared	GALA protein	<i>P</i> value
UK+ (<i>n</i> = 26) <i>vs</i> UK– (<i>n</i> = 6)	ash	0.0007
	cat	0.0011
	gol	0.0018
	lon	0.0006
	pat	0.0006
UKClin+ (<i>n</i> = 11) <i>vs</i> UK– (<i>n</i> = 6)	ash	0.0011
	cat	0.0077
	gol	0.0011
	lon	0.0022
	pat	0.0104
US+ (<i>n</i> = 48) <i>vs</i> US– (<i>n</i> = 3)	ash	0.0172
	cat	0.0356
	gol	0.0392
	lon	0.0213
	Pat	0.0192

Horses were naturally infected or subjected to experimental infection. UK+ comprised 26 cyathostomin naturally-infected horses sampled at an abattoir. UK– comprised 6 cyathostomin-negative ponies raised helminth-free. UKClin+ comprised 11 equids with larval cyathostominosis. US+ (*n* = 48) comprised naturally or experimentally infected equids from the USA. US– comprised 3 experimental equids from the US raised cyathostomin-free. For the infected groups (UK+, UKClin+, US+), group medians of the percentage positivity were compared with that of cyathostomin-free horses (UK– and US–) by the Mann–Whitney test. A *P* value <0.05 was taken to indicate statistical significance.

The development of a diagnostic test for cyathostomins is complicated by the complex nature of this group of nematodes. There are 50 recognized cyathostomin species (Lichtenfels *et al.* 2008); however, whilst a range of species is found in individuals, the majority of the burden has been found consistently across geographic regions to comprise 5–10 common species. The species investigated here were selected on the basis that they were the most prevalent species identified across multiple studies. In particular, *C. longibursatus* and *C. catinatum* are regularly recorded as the commonest species recovered from horses (Krecek *et al.* 1989 [South Africa]; Mfitlodze and Hutchinson, 1990 [Tropical Australia]; Bucknell *et al.* 1995 [Victoria, Australia]; Gawor, 1995 [Poland]; Lichtenfels *et al.* 2001 [UK], Chapman *et al.* 2002a [USA]; Boxell *et al.* 2004 [Western Australia]; Kuzmina *et al.* 2005 [Ukraine]). A representative protein for *C. ashworthi* was also selected here. This species has been regarded as a synonym of *Cylicocyclus nassatus*; the two are similar morphologically but are now regarded as separate (Lichtenfels *et al.* 1997). Earlier studies may have misidentified *C. ashworthi* (Chapman *et al.* 2002a), so this species may have been under-represented. Indeed, where *C. ashworthi*

has been defined as distinct from *C. nassatus*, it has been found at high prevalence (Lichtenfels *et al.* 2001; Kuzmina *et al.* 2005; Kornaš *et al.* 2009). Likewise, *C. goldi* and *C. pateratum* are species detected in high abundance in surveys performed in different regions (Reinemeyer *et al.* 1984; Krecek *et al.* 1989; Mfitlodze and Hutchinson, 1990; Gawor, 1995; Collobert-Laugier *et al.* 2002; Boxell *et al.* 2004; Traversa *et al.* 2010). As there does not appear to have been an obvious shift in the prevalence ranking of cyathostomin species over time, despite the advent and spread of anthelmintic resistance (Chapman *et al.* 2002a), it is with confidence that inclusion of the species here represent common components of cyathostomin infections now, as well as in the future.

The level of intra-specific variation observed in the GALA sequence was low in all species studied (Table 1). Further, the diversity observed in GALA sequence between these species was far lower than that seen when the GALA sequences were compared with orthologous sequences present in non-cyathostomin species (data not shown), thus indicating that the test is unlikely to be affected by cross reactivity to non-cyathostomin infections. In agreement with this, the specificity of each recombinant GALA protein was confirmed in immunoblotting experiments when each was probed with sera from horses specifically infected with large strongyle species, *P. equorum* or *S. westeri*, and no reactivity was observed. Further immunoblotting experiments demonstrated that all four GALA proteins bound strongly to IgG (T) in serum pooled from CI horses and in serum from clinical cases of larval cyathostominosis. These results were substantiated by the ELISA data, which demonstrated significantly higher specific serum IgG(T) levels to each GALA protein in the USA and UK CI groups compared with the respective cyathostomin negative groups (Table 2). The time course study supported these findings, demonstrating robust anti-GALA serum IgG(T) responses in all infected ponies. Similar to previous results obtained with Cy-GALA-pat (McWilliam *et al.* 2010) and with native antigens (Dowdall *et al.* 2002), specific IgG(T) increased to GALA-ash, -gol and -lon in Pony 104 earlier than in the other infected ponies. The more severe clinical parameters observed in Pony 104 indicated that it had developed the greatest burden of mucosal larvae during the infection protocol and, when this animal was euthanized (at 20 weeks post-infection), it was found to have a very high (>700 000 cyathostomin larvae) burden (Murphy and Love, 1997). The other two ponies had substantially lower burdens, but they were not necropsied until 60 and 62 weeks post-infection. The differences in the dynamics in IgG(T) response to the GALA-cat protein may reflect the relative proportions in species present over the trickle infection period (Murphy and Love, 1997). The observations

Table 3. Receiver operator characteristic (ROC) curve analysis of ELISA data relating to antigen-specific IgG(T) levels in horses comparing cyathostomin-positive *vs* cyathostomin-negative horses

Protein	AUC* (95% CI)	P value	Cut-off	Sensitivity % (95% CI)	Specificity % (95% CI)
ash	0.94 (0.87–0.99)	<0.0001	>9.76	82.43 (71.83–90.30)	100.00 (66.37–100.00)
cat	0.91 (0.82–1.01)	<0.0001	>5.94	95.95 (88.61–99.16)	77.78 (39.9–97.19)
gol	0.90 (0.82–1.00)	<0.0001	>9.24	91.89 (83.18–96.97)	77.78 (39.99–97.19)
lon	0.94 (0.88–1.00)	<0.0001	>16.69	75.68 (64.31–84.90)	100.00 (66.37–100.00)
pat	0.93 (0.86–1.00)	<0.0001	>7.40	86.49 (76.55–93.32)	88.89 (51.75–99.72)

Horses were naturally infected or subjected to experimental infection. The UK population comprised 26 cyathostomin-positive and 6 cyathostomin (true) negative equids. The US population comprised 48 cyathostomin-positive and 3 cyathostomin (true) negative equids. The area under the curve (AUC), 95% confidence intervals (CI) and *P* values for data generated by ROC curve analysis for each protein are shown. A cut-off percentage positivity value indicated for each protein is based on the value calculated as the highest sum of percentage sensitivity and specificity values obtained in the ROC analysis.

Table 4. Receiver operator characteristic (ROC) curve analysis of ELISA data relating to antigen-specific IgG(T) levels in horses from the UK and USA at various thresholds of larvae in the mucosa (total mucosal burden, TMB) and of larvae in the mucosa plus lumen (total worm burden, TWB)

Protein	AUC* (95% CI)	P value	Cut-off	Sensitivity% (95% CI)	Specificity% (95% CI)
TMB 0 larvae; Negatives: 17, Positives: 66					
ash	0.72 (0.57–0.87)	0.006	>8.88	87.88 (77.51–94.62)	52.94 (27.81–77.02)
cat	0.74 (0.58–0.89)	0.003	>6.72	92.42 (83.20–97.49)	52.94 (27.81–77.02)
gol	0.72 (0.577–0.87)	0.004	>11.36	78.79 (66.98–87.89)	64.71 (38.33–85.79)
lon	0.76 (0.616–0.89)	0.001	>16.69	77.27 (65.30–86.69)	70.59 (44.04–89.69)
pat	0.73 (0.57–0.89)	0.004	>9.78	74.24 (61.99–84.22)	76.47 (50.10–93.19)
TWB 0 larvae; Negatives: 10, Positives: 73					
ash	0.91 (0.83–0.99)	<0.0001	>9.76	82.19 (71.47–90.16)	90.00 (55.50–99.75)
cat	0.92 (0.83–1.00)	<0.0001	>6.53	93.15 (84.74–97.74)	80.00 (44.39–97.48)
gol	0.91 (0.82–0.99)	<0.0001	>10.11	90.41 (81.24–96.06)	80.00 (44.39–97.48)
lon	0.93 (0.86–0.99)	<0.0001	>16.69	76.71 (65.35–85.81)	100.00 (69.15–100.00)
pat	0.92 (0.85–0.99)	<0.0001	>9.78	72.60 (60.91–82.39)	100.00 (69.15–100.00)
TMB 5000 larvae; Negatives: 30, Positives: 53					
ash	0.69 (0.57–0.81)	0.004	>10.24	83.02 (70.20–91.93)	50.0 (31.30–68.70)
cat	0.77 (0.66–0.88)	<0.0001	>11.25	71.7 (57.65–83.21)	76.67 (57.72–90.07)
gol	0.70 (0.58–0.82)	0.002	>20.90	66.04 (51.73–78.48)	70 (50.60–85.27)
lon	0.74 (0.63–0.86)	0.0003	>31.17	60.38 (46.0–73.55)	83.33 (65.28–94.36)
pat	0.74 (0.63–0.86)	0.0002	>9.780	81.13 (68.03–90.56)	66.67 (47.19–82.71)
TWB 5000 larvae; Negatives: 18, Positives: 65					
ash	0.75 (0.61–0.88)	0.0015	>8.880	89.23 (79.06–95.56)	55.56 (30.76–78.47)
cat	0.82 (0.70–0.94)	<0.0001	>11.25	66.15 (53.35–77.43)	88.89 (65.29–98.62)
gol	0.79 (0.67–0.91)	0.0002	>19.72	64.62 (51.77–76.08)	83.33 (58.58–96.42)
lon	0.82 (0.71–0.93)	<0.0001	>17.89	76.92 (64.81–86.47)	83.33 (58.58–96.42)
pat	0.78 (0.66–0.90)	0.0003	>10.78	64.62 (51.77–76.08)	83.33 (58.58–96.42)

Horses were naturally infected or subjected to experimental infection. The area under the curve (AUC), 95% confidence intervals (CI), *P* values, cut-off values and % sensitivity and specificity are shown.

here indicate that the long-term goal of this work should be the development of a test incorporating several GALA proteins derived from the commonest species due to the potential risk of false negative results in some individuals in which a single species may be less abundant.

The ROC AUC values indicate that all proteins provide excellent discriminatory information when comparing true cyathostomin negative with true

cyathostomin positive individuals (Table 3). The AUC values obtained were similar for all five GALA proteins. When horses were stratified on the basis of mucosal larval burden (Table 4), the derived ROC AUC values were lower than the values obtained when the true cyathostomin negative group was compared with the cyathostomin positive horses. This is likely due to the fact that some horses in the TMB-negative group harboured

luminal stages of cyathostomins; such horses may have residual GALA-specific IgG(T) in their serum stimulated by recent encysted larval infection. This observation is unlikely to be due to cross-reactivity to antigens in luminal worms, as it was demonstrated previously that GALA protein and *gala* transcript could not be detected in these stages (McWilliam *et al.* 2010). The serum half-life of equine IgG(T) has been measured as 21 days (Sheoran *et al.* 2000), so a limitation of this test is that, in horses that have had recent emergence of encysted larvae or have received a recent effective larvicidal treatment, GALA-specific IgG(T) levels will still be elevated. With this in mind, a future objective will be to investigate the dynamics of circulating GALA protein-specific serum IgG(T) after anthelmintic treatments known to be effective against encysted larval stages. This issue is not unique to the cyathostomin test and is a concern with the commercially-available diagnostic assay for the tapeworm, *Anoplocephala perfoliata*, in horses. The tapeworm diagnostic is also based on the binding of serum IgG(T) to parasite proteins (Barrett *et al.* 2004; Abbott *et al.* 2008). Despite these concerns, the *A. perfoliata* ELISA is still regarded as a useful tool in practice (Kjaer *et al.* 2007; Abbott and Barrett, 2008). For these reasons, the test output must always be interpreted alongside the clinical and treatment history of the individual or population of animals being assessed.

In terms of informing on cyathostomin burden, the GALA tests performed well when used to discriminate horses at an encysted larval burden threshold of 5000 worms (Table 4). At higher TMB thresholds (10 000 +), the ROC AUC values were lower (i.e. <0.7) indicating that the tests could not discriminate well horses above and below thresholds >10 000 larvae. When the ROC curve analysis was repeated with horses segregated on the basis of threshold of TWB (i.e. mucosal and luminal nematode burdens, Table 4), the AUC values obtained were higher at the 5000 TWB threshold compared with when the horses were grouped according to TMB. Again, with this in mind, the test results will need to be interpreted in the context of the clinical or treatment history and also with respect to the time of year that the sample is analysed. In northern temperate climates, experimental studies (Reinemeyer *et al.* 1986) have shown a peak of cyathostomin larval luminal stages in spring (presumably derived from emerged encysted larvae acquired during the previous season). These larvae develop to adults in late spring, which persist through summer and are added to by immature worms, which co-contribute to a second adult worm peak in late summer. In the Reinemeyer *et al.* (1986) studies, there was a loss of luminal stages in autumn; hence, the GALA ELISA is likely to provide most diagnostic value if

used in these regions in autumn and winter when it can be used to inform on the need for larvicidal treatment, as well as in the differential diagnosis of the disease in horses presenting with weight loss and/or diarrhoea. A cocktail of the five proteins, and combinations thereof, will now be assessed to examine which should be combined to optimise the test. A balance will need to be struck between the resource required to generate each protein and the diagnostic value provided by the various combinations.

ACKNOWLEDGEMENTS

The authors would like to thank all veterinary surgeons who supplied the sera used in this study and Professor Tom Klei (Louisiana State University, USA) and Professor Sandy Love (University of Glasgow) for the supply of sera from the experimental studies.

FINANCIAL SUPPORT

The authors would like to thank the Horserace Betting Levy Board (HBLB, Project Grant 723 to JBM) and the Thoroughbred Breeders Association (Part contribution of project grant awarded by HBLB to JBM) for their generous financial support of this project.

REFERENCES

- Abbott, J. B. and Barrett, E. J. (2008). The problem of diagnosing tapeworm infections in horses. *Equine Veterinary Journal* **40**, 5–6.
- Abbott, J. B., Mellor, D. J., Barrett, E. J., Proudman, C. J. and Love, S. (2008). Serological changes observed in horses infected with *Anoplocephala perfoliata* after treatment with praziquantel and natural reinfection. *Veterinary Record* **162**, 50–53.
- Barrett, E. J., Farlam, J. and Proudman, C. J. (2004). Field trial of the efficacy of a combination of ivermectin and praziquantel in horses infected with roundworms and tapeworms. *Veterinary Record* **154**, 323–325.
- Boxell, A. C., Gibson, K. T., Hobbs, R. P. and Thompson, R. C. (2004). Occurrence of gastrointestinal parasites in horses in metropolitan Perth, Western Australia. *Australian Veterinary Journal* **82**, 91–95.
- Bucknell, D. G., Gasser, R. B. and Beveridge, I. (1995). The prevalence and epidemiology of gastrointestinal parasites of horses in Victoria, Australia. *International Journal for Parasitology* **25**, 711–724.
- Canevar, R. J., Braga, P. R., Boeckh, A., Grycajuck, M., Bier, D. and Molento, M. B. (2013). Lack of cyathostomin sp. reduction after anthelmintic treatment in horses in Brazil. *Veterinary Parasitology* **194**, 35–39.
- Chapman, M. R., French, D. D. and Klei, T. R. (2002a). Gastrointestinal helminths of ponies in Louisiana: a comparison of species currently prevalent with those present 20 years ago. *Journal of Parasitology* **88**, 1130–1134.
- Chapman, M. R., French, D. D., Taylor, H. W. and Klei, T. R. (2002b). One season of pasture exposure fails to induce a protective resistance to cyathostomins but increases numbers of hypobiotic third stage larvae. *Journal of Parasitology* **88**, 678–683.
- Collobert-Laugier, C., Hoste, H., Sevin, C. and Dorchies, P. (2002). Prevalence, abundance and site distribution of equine small strongyles in Normandy, France. *Veterinary Parasitology* **110**, 77–83.
- Dowdall, S. M. J., Matthews, J. B., Mair, T., Murphy, D., Love, S. and Proudman, C. J. (2002). Antigen-specific IgG(T) responses in natural and experimental Cyathostominae infection in horses. *Veterinary Parasitology* **106**, 225–242.
- Dowdall, S. M. J., Proudman, C. J., Love, S., Murphy, D., Klei, T. R. and Matthews, J. B. (2003). Purification and analyses of the specificity of two putative diagnostic antigens for larval cyathostomin infection in horses. *Research in Veterinary Science* **75**, 223–229.
- Dowdall, S. M., Proudman, C. J., Klei, T. R., Mair, T. S. and Matthews, J. B. (2004). Antigen-specific IgG(T) responses as a marker for larval cyathostomin infection. *International Journal for Parasitology* **34**, 101–108.
- Gawor, J. J. (1995). The prevalence and abundance of internal parasites in working horses autopsied in Poland. *Veterinary Parasitology* **58**, 99–108.

- Geurden, T., van Doorn, D., Claerebout, E., Kooyman, F., De Keersmaecker, S., Vercruysse, J., Besognet, B., Vanimisetti, B., di Regalbono, A. F., Beraldo, P., Di Cesare, A. and Traversa, D. (2014). Decreased strongyle egg reappearance period after treatment with ivermectin and moxidectin in horses in Belgium, Italy and The Netherlands. *Veterinary Parasitology* **204**, 291–296.
- Gibson, T. E. (1953). The effect of repeated anthelmintic treatment with phenothiazine on the faecal egg counts of housed horses, with some observations on the life cycle of *Trichonema* species in the horse. *Journal of Helminthology* **27**, 29–40.
- Giles, C. J., Urquhart, K. A. and Longstaffe, J. A. (1985). Larval cyathostomiasis (immature trichonema-induced enteropathy): a report of 15 clinical cases. *Equine Veterinary Journal* **17**, 196–201.
- Hodgkinson, J. E., Lichtenfels, J. R., Mair, T. S., Cripps, P., Freeman, K. L., Ramsey, Y. H., Love, S. and Matthews, J. B. (2003). A PCR-ELISA for the identification of cyathostomin fourth-stage larvae from clinical cases of larval cyathostomiasis. *International Journal for Parasitology* **33**, 1427–1435.
- Kaplan, R. M. (2002). Anthelmintic resistance in nematodes of horses. *Veterinary Research* **33**, 491–507.
- Kjaer, L. N., Lungholt, M. M., Nielsen, M. K., Olsen, S. N. and Maddox-Hyttel, C. (2007). Interpretation of serum antibody response to *Anoplocephala perfoliata* in relation to parasite burden and faecal egg count. *Equine Veterinary Journal* **39**, 529–533.
- Klei, T. R., Torbert, B. J., Chapman, M. R. and Ochoa, R. (1982). Irradiated larval vaccination of ponies against *Strongylus vulgaris*. *Journal of Parasitology* **68**, 561–569.
- Kornaś, S., Skalska, M., Nowosad, B., Gawor, J., Kharchenko, V. and Cabaret, J. (2009). Occurrence of strongyles (Strongylidae) in horses from small farms on the basis of necropsy. *Polish Journal of Veterinary Science* **12**, 225–230.
- Krecek, R. C., Reinecke, R. K. and Horak, I. G. (1989). Internal parasites of horses on mixed grassveld and bushveld in Transvaal, Republic of South Africa. *Veterinary Parasitology* **34**, 135–143.
- Kuzmina, T. A., Kharchenko, V. A., Starovir, A. I. and Dvojnjos, G. M. (2005). Analysis of the strongylid nematodes (Nematoda: Strongylidae) community after deworming of brood horses in Ukraine. *Veterinary Parasitology* **131**, 283–290.
- Lake, S. L., Matthews, J. B., Kaplan, R. M. and Hodgkinson, J. E. (2009). Determination of genomic DNA sequences for beta-tubulin isotype 1 from multiple species of cyathostomin and detection of resistance alleles in third-stage larvae from horses with naturally acquired infections. *Parasites and Vectors* **2** (Suppl 2), S6.
- Larkin, M. A., Blackshields, G., Brown, N. P., Chenna, R., McGettigan, P. A., McWilliam, H., Valentin, F., Wallace, I. M., Wilm, A., Lopez, R., Thompson, J. D., Gibson, T. J. and Higgins, D. G. (2007). Clustal W and Clustal X version 2.0. *Bioinformatics* **23**, 2947–2948.
- Lester, H. E. and Matthews, J. B. (2014). Faecal worm egg count analysis for targeting anthelmintic treatment in horses: points to consider. *Equine Veterinary Journal* **46**, 139–145.
- Lichtenfels, J. R., Kharchenko, V. A., Sommer, C. and Ito, M. (1997). Key characters for the microscopical identification of *Cylicocyclus nassatus* and *Cylicocyclus ashworthi* (Nematoda: Cyathostominae) of the horse *Equus caballus*. *Journal of the Helminthological Society of Washington* **64**, 120–127.
- Lichtenfels, J. R., McDonnell, A., Love, S. and Matthews, J. B. (2001). Nematodes of the tribe Cyathostominae (Strongylidae) collected from horses in Scotland. *Comparative Parasitology* **68**, 265–268.
- Lichtenfels, J. R., Kharchenko, V. A. and Dvojnjos, G. M. (2008). Illustrated identification keys to strongylid parasites (Strongylidae: Nematoda) of horses, zebras and asses (Equidae). *Veterinary Parasitology* **156**, 4–161.
- Love, S., Mair, T. S. and Hillyer, M. H. (1992). Chronic diarrhoea in adult horses: a review of 51 referred cases. *Veterinary Record* **130**, 217–219.
- Mair, T. S. (1993). Recurrent diarrhoea in aged ponies associated with larval cyathostomiasis. *Equine Veterinary Journal* **25**, 161–163.
- Marchler-Bauer, A., Anderson, J. B., Derbyshire, M. K., DeWeese-Scott, C., Gonzales, N. R., Gwadz, M., Hao, L., He, S., Hurwitz, D. I., Jackson, J. D., Ke, Z., Krylov, D., Lanczycki, C. J., Liebert, C. A., Liu, C., Lu, F., Lu, S., Marchler, G. H., Mullokandov, M., Song, J. S., Thanki, N., Yamashita, R. A., Yin, J. J., Zhang, D. and Bryant, S. H. (2007). CDD: a conserved domain database for interactive domain family analysis. *Nucleic Acids Research* **35**, D237–D240.
- Matthews, J. B. (2008). An update on cyathostomins: anthelmintic resistance and worm control. *Equine Veterinary Education* **20**, 552–560.
- Matthews, J. B. (2014). Anthelmintic resistance in equine nematodes. *International Journal for Parasitology: Drugs and Drug Resistance* **4**, 310–315.
- McWilliam, H. E. G., Nisbet, A. J., Dowdall, S. M. J., Hodgkinson, J. E. and Matthews, J. B. (2010). Identification and characterisation of a potential immunodiagnostic marker for larval cyathostomiasis. *International Journal for Parasitology* **40**, 265–275.
- Mfitilodze, M. W. and Hutchinson, G. W. (1990). Prevalence and abundance of equine strongyles (Nematoda: Strongyloidea) in tropical Australia. *Journal of Parasitology* **76**, 487–494.
- Monahan, C. M., Chapman, M. R., Taylor, H. W., French, D. D. and Klei, T. R. (1996). Comparison of moxidectin oral gel and ivermectin oral paste against a spectrum of internal parasites of ponies with special attention to encysted cyathostome larvae. *Veterinary Parasitology* **63**, 225–235.
- Monahan, C. M., Chapman, M. R., Taylor, H. W., French, D. D. and Klei, T. R. (1997). Foals raised on pasture with or without daily pyrantel tartrate feed additive: comparison of parasite burdens and host responses following experimental challenge with large and small strongyle larvae. *Veterinary Parasitology* **73**, 277–289.
- Monahan, C. M., Chapman, M. R., Taylor, H. W., French, D. D. and Klei, T. R. (1998). Experimental cyathostome challenge of ponies maintained with or without benefit of daily pyrantel tartrate feed additive: comparison of parasite burdens, immunity and colonic pathology. *Veterinary Parasitology* **74**, 229–241.
- Murphy, D. and Love, S. (1997). The pathogenic effects of experimental cyathostome infections in ponies. *Veterinary Parasitology* **70**, 99–110.
- Nielsen, M. K. (2012). Sustainable equine parasite control: perspectives and research needs. *Veterinary Parasitology* **185**, 32–44.
- Nielsen, M. K., Haaning, N. and Olsen, S. N. (2006). Strongyle egg shedding consistency in horses on farms using selective therapy in Denmark. *Veterinary Parasitology* **135**, 333–335.
- Nielsen, M. K., Pfister, K. and von Samson-Himmelstjerna, G. (2014). Selective therapy in equine parasite control—application and limitations. *Veterinary Parasitology* **202**, 95–103.
- Ogbourne, C. P. (1976). The prevalence, relative abundance and site distribution of nematodes of the subfamily Cyathostominae in horses killed in Britain. *Journal of Helminthology* **50**, 203–214.
- Petersen, T. N., Brunak von Heijne, G. and Nielsen, H. (2011). SignalP 4.0: discriminating signal peptides from transmembrane regions. *Nature Methods* **8**, 785–786.
- Reinemeyer, C. R., Smith, S. A., Gabel, A. A. and Herd, R. P. (1984). The prevalence and intensity of internal parasites of horses in the USA. *Veterinary Parasitology* **15**, 75–83.
- Reinemeyer, C. R., Smith, S. A., Gabel, A. A. and Herd, R. P. (1986). Observations on the population dynamics of five cyathostome nematode species of horses in northern USA. *Equine Veterinary Journal* **18**, 121–124.
- Reinemeyer, C. R., Prado, J. C. and Nielsen, M. K. (2016). Comparison of the larvicidal efficacies of moxidectin or a five-day regimen of fenbendazole in horses harboring cyathostomin populations resistant to the adjuvant dosage of fenbendazole. *Veterinary Parasitology* **214**, 100–107.
- Reid, S. W., Mair, T. S., Hillyer, M. H. and Love, S. (1995). Epidemiological risk factors associated with a diagnosis of clinical cyathostomiasis in the horse. *Equine Veterinary Journal* **27**, 127–130.
- Relf, V. E., Lester, H. E., Morgan, E. R., Hodgkinson, J. E. and Matthews, J. B. (2014). Anthelmintic efficacy on UK Thoroughbred stud farms. *International Journal for Parasitology* **44**, 507–514.
- Rossano, M. G., Smith, A. R. and Lyons, E. T. (2010). Shortened strongyle-type egg reappearance periods in naturally infected horses treated with moxidectin and failure of a larvicidal dose of fenbendazole to reduce fecal egg counts. *Veterinary Parasitology* **173**, 349–352.
- Sangster, N. C. (1999). Pharmacology of anthelmintic resistance in cyathostomes: will it occur with the avermectin/milbemycins? *Veterinary Parasitology* **85**, 189–201.
- Sheoran, A. S., Timoney, J. F., Holmes, M. A., Karzenski, S. S. and Crisman, M. V. (2000). Immunoglobulin isotypes in sera and nasal mucosal secretions and their neonatal transfer and distribution in horses. *American Journal of Veterinary Research* **61**, 1099–1105.
- Smith, H. J. (1976). Strongyle infections in ponies. 1. Response to intermittent thiabendazole treatment. *Canadian Journal of Comparative Medicine* **40**, 334–340.
- Stratford, C. H., Lester, H. E., Morgan, E. R., Pickles, K. J., Relf, V., McGorum, B. C. and Matthews, J. B. (2014). A questionnaire study of equine gastrointestinal parasite control in Scotland. *Equine Veterinary Journal* **46**, 25–31.
- Swets, J. A. (1988). Measuring the accuracy of diagnostic systems. *Science* **240**, 1285–1293.
- Traversa, D., Milillo, P., Barnes, H., von Samson-Himmelstjerna, G., Schurmann, S., Demeler, J., Otranto, D., Lia, R. P., Perrucci, S., Frangipane di Regalbono, A., Beraldo, P., Amodie, D., Rohn, K., Cobb, R. and Boeckh, A. (2010). Distribution and species-specific occurrence of cyathostomins (Nematoda, Strongylida) in naturally infected horses from Italy, United Kingdom and Germany. *Veterinary Parasitology* **168**, 84–92.